Treating Paget's Disease-Why and How Much? - Wikidata - wikimedia - TriplyDB

Treating Paget's Disease-Why and How Much?

Treating Paget's Disease-Why and How Much?

http://www.wikidata.org/entity/Q54163461

about

Treating Paget's Disease-Why and How Much?

http://www.wikidata.org/entity/Q54163461

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treating Paget's Disease-Why and How Much?

@en

Treating Paget's Disease-Why and How Much?

@nl

type

label

Treating Paget's Disease-Why and How Much?

@en

Treating Paget's Disease-Why and How Much?

@nl

prefLabel

Treating Paget's Disease-Why and How Much?

@en

Treating Paget's Disease-Why and How Much?

@nl

P1433

Q54163461-361A4A9A-46D9-4194-AB95-B297949E69D9

P1476

Q54163461-EC77A852-62A1-4B1E-93B4-01A77163BE07

P2093

Q54163461-18A8B111-BFCC-494F-87BF-40151716091E

P2860

Q54163461-0077DA34-0267-4D8C-8BB1-07BCA66AB2C3

Q54163461-18D281CF-E9E1-4DE6-AF7B-6D1B31675CCE

Q54163461-250B680D-4522-4378-812F-74E9D3BAE784

Q54163461-2AD7FB2D-BBCF-44DF-9796-986C8474F91C

Q54163461-5ABE2886-D212-473F-9419-196F490A3A53

Q54163461-5BFAAD8C-72A9-4DD1-98A3-F076D5ED7A2B

Q54163461-CA0DAB7B-9A61-4B59-8C66-83AD55362BA4

Q54163461-CE94CB09-0FD9-4CC2-9035-95DA1B8744A6

Q54163461-E64BF6B6-19A1-44F5-97C0-BE86A44C9106

Q54163461-FFEF579B-835A-4574-A4EB-D0B3DE560E34

P304

Q54163461-E7B8C519-03E4-433B-8074-CCA513A72C8F

P31

Q54163461-2F5FDB01-7BD2-4866-88B0-BEBC72DF80A9

P356

Q54163461-78ED7A1C-848E-4613-9392-580F91C51CD1

P433

Q54163461-CAE9382A-0018-4B90-9AF4-93A95629E093

P478

Q54163461-9589BEAD-CCED-4183-8CBA-1AEE52E71310

P577

Q54163461-031187EE-2508-403D-B577-4AB63AF0A9A2

P698

Q54163461-0671292C-E15F-4CD6-9F5E-ADC8B9AB89E0

P356

P1433

Journal of Bone and Mineral Research

P1476

Treating Paget's Disease-Why and How Much?

@en

P2093

Tim Cundy

http://www.w3.org/2001/XMLSchema#string

P2860

A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study.

Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone.

The epidemiology of Paget's disease in Britain: is the prevalence decreasing?

Epidemiology of Paget's disease in Europe: the prevalence is decreasing.

Paget's disease of bone in New Zealand: continued decline in disease severity.

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

P304

1163-1164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.3156

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28430378

http://www.w3.org/2001/XMLSchema#string